Business Context and Reporting Period
Company: Novavax, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2010
Business Overview: Novavax is a clinical-stage biopharmaceutical company developing recombinant vaccines using its virus-like-particle (VLP) platform. Key product targets include pandemic influenza (H5N1, H1N1), seasonal influenza, Respiratory Syncytial Virus (RSV), and Varicella Zoster Virus (VZV). The company has not yet generated significant product revenue and relies on equity financing and government contracts.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2010 | Nine Months Ended Sep 30, 2010 | Balance Sheet (Sep 30, 2010) |
|---|---|---|---|
| Revenue | $175 | $292 | N/A |
| Net Loss | $(10,355) | $(31,194) | N/A |
| Net Loss Per Share | $(0.10) | $(0.30) | N/A |
| Operating Expenses | $10,714 | $31,754 | N/A |
| Cash & Cash Equivalents | N/A | N/A | $16,215 |
| Short-Term Investments | N/A | N/A | $20,648 |
| Total Assets | N/A | N/A | $79,314 |
| Total Liabilities | N/A | N/A | $12,321 |
| Working Capital | N/A | N/A | $28,282 |
Note: Revenue is primarily derived from services performed under contracts with U.S. government agencies. The company reported no product sales.
Material Changes vs. Prior Period
- Revenue: Revenue for the nine months ended September 30, 2010, increased to $0.3 million from $0.25 million in the prior year period. For the three-month period, revenue decreased slightly to $0.175 million from $0.201 million.
- Operating Expenses: Total operating expenses increased significantly to $31.8 million for the nine months ended September 30, 2010, compared to $23.5 million in the prior year. This 35% increase was driven primarily by Research and Development (R&D) expenses, which rose to $23.2 million (from $14.8 million) due to clinical trial costs for H1N1 and seasonal influenza candidates.
- Net Loss: Net loss widened to $31.2 million for the nine-month period (from $24.4 million) and $10.4 million for the quarter (from $7.5 million), reflecting the surge in R&D spending.
- Liquidity: Cash and cash equivalents decreased from $38.8 million at year-end 2009 to $16.2 million at September 30, 2010. However, short-term investments increased from $4.2 million to $20.6 million as the company deployed cash into commercial paper and corporate notes.
- Financing: The company raised $22.1 million in net proceeds from the sale of common stock under its At Market Issuance Sales Agreement during the nine-month period.
Outlook, Risks, and Management Commentary
- Liquidity Outlook: Management believes current cash, investments, and anticipated proceeds from its At Market Issuance Sales Agreement will fund operations for at least the next twelve months. However, additional capital will be required for future clinical trials and commercialization.
- Clinical Progress:
- H1N1: Completed a two-stage clinical trial in Mexico with positive safety and immunogenicity results. The final Clinical Study Report is expected by the end of 2010.
- Seasonal Influenza: Phase II trials in healthy adults and older adults showed the vaccine was well-tolerated and immunogenic.
- RSV: An Investigational New Drug (IND) application was filed in September 2010 but placed on clinical hold by the FDA due to questions regarding chemistry, manufacturing, and controls (CMC). Management expects written communication from the FDA by mid-November 2010.
- Government Contracts: The company is awaiting a determination from HHS BARDA regarding a contract for the advanced development of recombinant influenza vaccines. The proposal is in the competitive range, but no award is guaranteed.
- Risks:
- Failure to secure the HHS BARDA contract or other financing.
- Regulatory delays, specifically the clinical hold on the RSV program.
- Manufacturing scale-up challenges and dependence on third-party manufacturers.
- Legal proceedings against former directors for the collection of $1.57 million in defaulted notes.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $36.9 million in liquid assets (cash + short-term investments) against the projected burn rate, given the significant increase in R&D spending.
- RSV Clinical Hold: Monitor the resolution of the FDA clinical hold on the RSV vaccine program, as this is a critical near-term milestone.
- HHS BARDA Contract: Track the status of the HHS BARDA contract award, which is a potential source of non-dilutive funding but remains uncertain.
- Dilution Risk: Assess the impact of continued equity financing under the At Market Issuance Sales Agreement on existing shareholders.
- Legal Contingencies: Review the status of the lawsuits against former directors regarding the $1.57 million in outstanding notes.